צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Minerva (NERV)

Sales dynamics based on the rolling 12-month year-over-year growth rate are tied to the FDA approval of roluperidone. The model relies on full outsourcing of production and testing, while patent protection creates a significant barrier to entry. Meanwhile, 0.00 records a new level, visualizing the market consensus regarding the revenue expansion rates of Minerva Neurosciences (NERV).
פילוחי נתונים אנליטיים מרוכזים עבור Minerva (NERV)

Effective asset selection requires a rigorous analysis of revenue dynamics to assess business viability. This indicator measures the daily change in aggregate revenues over a rolling year, reflecting the actual pace of commercial development. For Minerva Neurosciences (NERV), amid regulatory risks and tightening liquidity, this parameter becomes a critical marker of survival. The current value of 0.00 confirms a stage of financial instability. Evaluate the LTM annual sales growth rate as a signal of the issuer's potential resource depletion.